Lamellasome™ and pulmonary diseases

LAMELLASOME™ products are engineered to treat complex lung disorders, based on their ability to:

  • Reduce inflammatory responses in pulmonary tissue.
  • Interrupt the onset and progression of pulmonary fibrosis.
  • Modulate tissue surface tension, moisture retention and lubrication. 

Our lead product, IPF-Lamellasome, has demonstrated the ability to significantly decrease well established markers of pulmonary fibrosis in vivo in a large animal model by reducing both myofibroblasts and collagen production1.

These antifibrotic properties are applicable to a range of other interstitial lung diseases such as Drug-induced Interstitial Lung Disease (ILD), Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS, including COVID-19) and Radiotherapy-Induced Lung Injury (RILI).

Muco-ease, another LAMELLASOME™ - based therapeutic, has been designed for the treatment of Cystic Fibrosis (CF) by improving mucociliary clearance thanks to its biophysical activity against all viscoelastic components of mature CF mucus. The combined antifibrotic and anti-infective properties of Muco-ease also have the potential to slow disease progression in mild to moderate CF:


  • Biophysical activity against mucin, in particular, makes it suitable for intervention early in disease. Maintaining mucin fluidity may modify the course of the disease.
  • Significantly increasing the fluidity of DNA compared to the current market leading mucolytic, Pulmozyme, which acts only on DNA.
  • Reducing the lung’s fibrotic response to inflammation.
  • Facilitating microbial clearance by disrupting quorum sensing and inhibiting biofilm. Supporting the lung’s immune defence.
  • When used with suboptimal dosing of Tazocin IV antibiotic, it provided resolution of lung infection, possibly through antibiotic potentiation and increased mucociliary clearance1

1Model of PA (LESB65) respiratory infection2. CFU counts following no treatment (PA only), LMS (LAMELLASOME™) alone, Tazocin alone or Tazocin + LMS (*=p<0.05, **=p<0.001). Treatments administered at 24 and 48 hours post infection.
2Nat Commun. 2014 Sep 2;5:4780. doi: 10.1038/ncomms5780



Safety profile
LAMELLASOME™ products have an excellent safety profile as demonstrated in repeat dosing of LAMELLASOME™ therapy in clinical studies of moderate to severe dry eye, as well as radiotherapy-induced xerostomia (dry mouth) in patients with head and neck cancer2.

GLP non-clinical safety and toxicity studies demonstrated:

  • Excellent safety and tolerability profile for oral and ocular tissues for cytotoxicity, genotoxicity, irritation and sensitisation.
  • Safe inhalation profile with very high NOAEL of ~4,000mg/day (standardised to a 60kg person) from maximum tolerated and long-term inhalation toxicology studies.

1 Collie, D., et al., Nebulisation of synthetic lamellar lipids mitigates radiation-induced lung injury in a large animal model. Scientific Reports, 2018. 8(1): p. 13316. CLICK HERE TO DOWNLOAD PDF
2 Paterson, C., et al. "Radiotherapy-induced xerostomia: a randomised, double-blind, controlled trial of Visco-ease™ oral spray compared with placebo in patients with cancer of the head and neck." British Journal of Oral and Maxillofacial Surgery, 2019, 57(10): p. 1119.

© Copyright 2021 Lamellar